CHARACTERIZATION OF DYSKINESIAS INDUCED BY L-DOPA IN MPTP-TREATED SQUIRREL-MONKEYS

被引:51
|
作者
BOYCE, S
RUPNIAK, NMJ
STEVENTON, MJ
IVERSEN, SD
机构
[1] Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Harlow, CM20 2QR, Essex, Terlings Park
关键词
Chorea; Dystonia; l-dopa; Parkinson's disease; Squirrel monkey;
D O I
10.1007/BF02245739
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Intermittent treatment with l-dopa over a 2-year period induced abnormal involuntary movements in MPTP-treated squirrel monkeys. Dyskinesias included a choreic and dystonic component. Dose-response curves for chorea and dystonia revealed that the same dose of l-dopa (30 mg/kg) induced the highest score for both dyskinesias; however, the severity was much greater for chorea. Choreic movements were always most prevalent at the time of peak effect, whereas dystonia was apparent at the time of peak effect and at "end-of-dose", and was occasionally observed spontaneously. Our findings indicate that squirrel monkeys treated with MPTP develop l-dopa-induced dyskinesias which closely resemble those observed in Parkinson's disease. This species provides a valuable animal model to develop improved therapeutic agents. © 1990 Springer-Verlag.
引用
收藏
页码:21 / 27
页数:7
相关论文
共 50 条
  • [21] L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates
    M. Kuoppamäki
    G. Al-Barghouthy
    M. J. Jackson
    L. A. Smith
    N. Quinn
    P. Jenner
    Journal of Neural Transmission, 2007, 114 : 1147 - 1153
  • [22] Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration
    Stephenson, DT
    Li, Q
    Simmons, C
    Connell, MA
    Meglasson, MD
    Merchant, K
    Emborg, ME
    EXPERIMENTAL NEUROLOGY, 2005, 193 (01) : 261 - 261
  • [23] Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with L-dopa
    Kuoppamaki, M
    Al-Barghouthy, G
    Jackson, M
    Smith, L
    Zeng, BY
    Quinn, N
    MOVEMENT DISORDERS, 2002, 17 : S18 - S18
  • [24] Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration
    Stephenson, DT
    Li, Q
    Simmons, C
    Connell, MA
    Meglasson, MD
    Merchant, K
    Emborg, ME
    NEUROBIOLOGY OF DISEASE, 2005, 20 (02) : 347 - 359
  • [25] The effects of pallidotomy on motor function in MPTP-treated, L-DOPA primed common marmosets
    Costa, SS
    Iravani, MM
    Jackson, MJ
    Jenner, P
    MOVEMENT DISORDERS, 2004, 19 : S319 - S319
  • [26] Nicotine alone and in combination with L-DOPA in MPTP induced hemiparkinsonian monkeys
    Domino, EF
    Ni, LS
    Zhang, HL
    ADDICTION, 1998, 93 (06) : 913 - 914
  • [27] Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys
    Grondin, R
    Tahar, AH
    Doan, VD
    Ladure, P
    Bédard, PJ
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2000, 361 (02) : 181 - 186
  • [28] (+)-PHNO - A NEW ANTI-PARKINSONIAN AGENT WHICH DOES NOT INDUCE CHOREA IN MPTP-TREATED SQUIRREL-MONKEYS
    RUPNIAK, NMJ
    BOYCE, S
    STEVENTON, MJ
    IVERSEN, SD
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1990, 53 (07): : 622 - 623
  • [29] Noradrenoceptor antagonism with idazoxan improves l-dopa-induced dyskinesias in MPTP monkeys
    R. Grondin
    Abdallah Hadj Tahar
    Van Diep Doan
    P. Ladure
    P.J. Bédard
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2000, 361 : 181 - 186
  • [30] Similarities and Differences in Cognitive Deficits and Responsiveness to L-Dopa Between Aged and MPTP-Treated Cynomolgus Monkeys Tested on the Same Tasks
    Yue, F.
    Chan, P.
    Wan, H.
    Weeks, R.
    Grondin, R.
    Than, Z.
    CELL TRANSPLANTATION, 2014, 23 (06) : 790 - 790